DeCure for Neurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for neurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNeurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for neurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
chromodomain helicase DNA binding protein 1 (CHD1) — CHD1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9EAR · 3.1 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
A 2020 letter notes that Fathalla and Salman reported homozygous mutations in the TRAPPC6B gene in a patient with neurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy, and that only eight similar cases had been published in the literature at that time. The 2024 case report describes a patient with acquired microcephaly, global developmental delay, and drug-resistant epilepsy whose brain MRI showed a Z-shaped brainstem, reduced white matter volume, diffuse corpus callosum thinning, and partial fusion of the cerebellar hemispheres. Whole-exome sequencing found a pathogenic ARF3 gene variant (c.200A>T, p.(Asp67Val)). The authors state that only two previous ARF3-associated cases had been documented, and that the phenotype aligns with Golgipathies.
Earlier reviews explain that congenital microcephaly is genetically and clinically heterogeneous, often inherited as recessive traits, and associated with intellectual disability and sometimes epilepsy. The 2017 update on autosomal recessive primary microcephaly (MCPH) notes that inconsistent features include hyperactivity, expressive speech disorder, and epilepsy. A 2023 case of hemimegalencephaly describes an atypical presentation with normal intellectual function and adult-onset nonrefractory epilepsy, contrasting with the classical infantile presentation of intractable epilepsy and developmental delay.
No drug treatment is mentioned in any of these abstracts. No clinical trial, no intervention, no survival or response rate data are reported. What is missing is any investigation of drug repurposing for this group of disorders, any systematic collection of patient outcomes beyond single case reports, and any funding or trial design aimed at testing a candidate therapy in a defined genetic subtype. Patient stratification by specific gene mutation (ARF3, TRAPPC6B, or others) would be necessary before any intervention could be rationally evaluated.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Neurology · 2001 · 241 citations
Molecular genetics of human microcephaly
AbstractHuman microcephaly comprises a heterogeneous group of conditions that are characterized by a failure of normal brain growth. Microcephaly can be caused by many injurious or degenerative conditions, or by developmental malformations in which the growth of the brain is impaired as a result of defects in pattern formation, cell proliferation, cell survival, cell differentiation, or cell growth. These latter forms of congenital microcephaly are frequently inherited, usually as recessive traits, and are associated with mental retardation and sometimes epilepsy. Some of the genes that cause congenital microcephaly are likely to control crucial aspects of neural development, and may also be involved in the evolutionary explosion of cortical size that characterizes primates. There has recently been a rapid advance in the use of genetic mapping techniques to identify genetic loci responsible for microcephaly. Although several loci have been mapped, the condition is clearly genetically and clinically heterogeneous.
Autosomal Recessive Primary Microcephaly (MCPH): An Update
AbstractAutosomal recessive primary microcephaly (MCPH; MicroCephaly Primary Hereditary) is a genetically heterogeneous neurodevelopmental disorder characterized by a significantly reduced head circumference present already at birth and intellectual disability. Inconsistent features include hyperactivity, an expressive speech disorder, and epilepsy. Here, we provide a brief overview on this rare disorder pertinent for clinicians.
American Journal of Medical Genetics Part A · 2024 · 2 citations
Neurodevelopmental disorder associated with gene <i>ARF3</i>: A case report
AbstractWe present a case study of a patient exhibiting acquired microcephaly along with global developmental delay and drug-resistant epilepsy. Brain magnetic resonance imaging revealed distinctive features, including a Z-shaped morphology of the brainstem, volumetric reduction of white matter, diffuse thinning of the corpus callosum, and partial fusion of the cerebellar hemispheres at their most cranial portion. Whole-exome sequencing uncovered a pathogenic variant in the ARF3 gene c.200A>T, p.(Asp67Val). The neurodevelopmental disorder associated with the ARF3 gene is exceptionally rare, with only two previously documented cases in the literature. This disorder is characterized by global developmental delay and brain malformations, particularly affecting the white matter, cerebellum, and brainstem. It can also manifest as acquired microcephaly and epilepsy. These phenotypic characteristics align with Golgipathies, underscoring the significance of considering this group of conditions in relevant clinical contexts. In cases where a Z-shaped morphology of the brainstem is observed, ARF3-associated disorder should be included in the list of differential diagnoses.
Ibnosina Journal of Medicine and Biomedical Sciences · 2020 · 0 citations · open access
Dental health and epilepsy: Important but too often ignored
AbstractWe read the article entitled “neurodevelopmental disorder with microcephaly, epilepsy, and brain atrophy” with a novel mutation in the recent issue of the journal with great interest. Fathalla and Salman reported homozygous mutations in the TRAPPC6B gene that presented with anatomical malformation of the skull and brain associated with epilepsy. One interesting fact was that there are only eight similar cases already published in the literature.[[1]]
Archives of Medicine and Health Sciences · 2023 · 0 citations · open access
Hemimegalencephaly with Adult-Onset Seizures and Normal Intellectual Function: A Rare Case Report
AbstractHemimegalencephaly (HME) is one of the rarest congenital malformations of the brain characterized by abnormal enlargement of a cerebral hemisphere. It can present as an isolated sporadic form or associated with other neurodevelopmental syndromes. The classical clinical manifestation develops in infancy or early childhood and includes intellectual impairment, developmental delay, intractable epilepsy, and motor abnormalities. We report here an atypical case of HME with normal intellectual functions and adult-onset nonrefractory epilepsy demonstrating the wide variation in clinical expressivity of the disease.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
